

## HR 4769

### Medicare Prescription Drug Savings and Choice Act of 2019

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Oct 21, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Oct 22, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/4769>

## Sponsor

**Name:** Rep. Schakowsky, Janice D. [D-IL-9]

**Party:** Democratic • **State:** IL • **Chamber:** House

## Cosponsors

No cosponsors are listed for this bill.

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 22, 2019
Ways and Means Committee	House	Referred To	Oct 21, 2019

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
116 S 2650	Identical bill	Oct 21, 2019: Read twice and referred to the Committee on Finance. (text: CR S5924-5925)

## **Medicare Prescription Drug Savings and Choice Act of 2019**

This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish at least one prescription drug plan that is operated by Medicare.

Among other things, the plan must (1) serve the entire United States; and (2) be the default plan for enrollees under the Medicare prescription drug benefit, unless the enrollee chooses another plan.

Additionally, the CMS must negotiate prices for prescription drugs that are covered under the plan and, if appropriate, encourage the use of more affordable therapeutic equivalents. (Currently, the CMS is prohibited from negotiating the prices of covered drugs under the Medicare prescription drug benefit.) The Agency for Healthcare Research and Quality must assess the clinical benefits of drugs and make recommendations to the CMS regarding price negotiations, based on specified information (e.g., comparable international prices).

### **Actions Timeline**

---

- **Oct 22, 2019:** Referred to the Subcommittee on Health.
- **Oct 21, 2019:** Introduced in House
- **Oct 21, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.